NASDAQ: ACRSAclaris Therapeutics Inc Stock
$1.33-0.03 (-2.21%)
Updated Apr 29, 2025
ACRS Price
$1.33
Fair Value Price
N/A
Market Cap
$143.53M
52 Week Low
$0.95
52 Week High
$5.17
P/E
-0.78x
P/B
0.92x
P/S
10.24x
PEG
N/A
Dividend Yield
N/A
Revenue
$18.72M
Earnings
-$132.07M
Gross Margin
17.4%
Operating Margin
-705.48%
Profit Margin
-705.5%
Debt to Equity
0.42
Operating Cash Flow
-$20M
Beta
1.18
Next Earnings
Jun 6, 2025
Ex-Dividend
N/A
Next Dividend
N/A
ACRS Overview
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ACRS's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Diagnostic & Research
Industry Rating
B
ACRS
Ranked#43 of 44
Ranked#43 of 44
Be the first to know about important ACRS news, forecast changes, insider trades & much more!
ACRS News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ACRS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ACRS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ACRS is good value based on its book value relative to its share price (0.92x), compared to the US Diagnostics & Research industry average (3.38x)
P/B vs Industry Valuation
ACRS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ACRS due diligence checks available for Premium users.
Valuation
ACRS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.78x
Industry
38.53x
Market
29.19x
ACRS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.92x
Industry
3.38x
ACRS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ACRS's financial health
Profit margin
Revenue
$9.2M
Net Income
-$96.6M
Profit Margin
-1,048.2%
ACRS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ACRS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$220.3M
Liabilities
$64.8M
Debt to equity
0.42
ACRS's short-term assets ($125.95M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ACRS's short-term assets ($125.95M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ACRS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ACRS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$8.9M
Investing
-$88.7M
Financing
$74.6M
ACRS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ACRS vs Diagnostic & Research Stocks
Aclaris Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.